Welcome to our dedicated page for Nls Pharmaceutic SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through NLS Pharmaceutics’ labyrinth of drug-development disclosures is no small task. Every 10-K packs dense clinical-trial tables, patent timelines, and risk factors that stretch far beyond routine revenue lines. Investors tracking how the Swiss biotech funds Phase 2 narcolepsy studies or books milestone payments often need to cross-reference amendments, 8-K updates, and dozens of Form 4 notices from scientific founders. If you have ever searched “where can I find NLS Pharmaceutics’ quarterly earnings reports?” or “what does NLS Pharmaceutics report in their SEC filings?” you already know the challenge.
Stock Titan brings clarity. Our AI reads each NLS Pharmaceutics quarterly earnings report 10-Q filing and NLS Pharmaceutics annual report 10-K simplified, then delivers plain-English highlights—cash runway, R&D spend, trial-enrollment progress—within seconds. Real-time alerts surface NLS Pharmaceutics Form 4 insider transactions real-time, while smart explanations turn opaque NLS Pharmaceutics 8-K material events explained into concise summaries you can act on. Whether you’re comparing pay in the latest NLS Pharmaceutics proxy statement executive compensation or reviewing NLS Pharmaceutics insider trading Form 4 transactions, the platform answers naturally voiced questions and links directly to the source documents.
- Track NLS Pharmaceutics executive stock transactions Form 4 in context of upcoming data releases.
- Spot trends with NLS Pharmaceutics earnings report filing analysis across quarters.
- Speed up due diligence by understanding NLS Pharmaceutics SEC documents with AI that flags pipeline catalysts and patent expirations.
From initial S-1 amendments to the latest disclosures, every NLS Pharmaceutics SEC filings explained simply is updated the moment it hits EDGAR—so you’re never a step behind.
NLS Pharmaceutics Ltd. – Schedule 13D filing (NLSPW)
Chairman Ronald Hafner has filed a Schedule 13D disclosing beneficial ownership of 557,131 common shares, equal to 13.2 % of the company’s 4,097,641 outstanding shares. Mr. Hafner possesses sole voting and dispositive power over the entire position; no shares are held jointly.
Capital deployment was entirely from personal funds. The filing details multiple transactions that built the position:
- Equity Purchase Agreement (10-Oct-2024): acquired 100,807 common shares plus 100,807 five-year warrants (exercise $4.25) at a combined price of $3.97.
- Warrant Amendment (9-Oct-2024): received pre-funded warrants for 1,925 shares, exercisable at CHF 0.80.
- Debt Purchase Agreement (10-Oct-2024): obtained 173,173 convertible preferred shares (conversion price $4.96) as part of a $4 m debt restructuring.
- Put-Call Agreement (Feb-2025): option exercised leading to purchase of 37,783 preferred shares for $150,000.
- Debt settlements: 111,637 common shares transferred from CEO Alexander Zwyer (7-Feb-2025) and 17,782 shares transferred from Magnetic Rock Investment AG (21-Feb-2025).
Intent: The shares are held for investment; no activist agenda is disclosed. The agreements grant limited participation rights (up to 50 % of future offerings for one year) but do not impose voting covenants. No criminal or civil proceedings are reported against the filer.
For investors, the filing signals material insider confidence and establishes Mr. Hafner as the company’s largest known shareholder, potentially aligning board decisions with shareholder value creation. No immediate dilution or earnings impact is indicated, but future conversions of preferred shares and warrant exercises could expand the float.
FAQ
What is the current stock price of Nls Pharmaceutic (NLSPW)?
